The transaction marks RPGAP’s second strategic acquisition following its recent acquisition of Actis Generics
Priority-reviewed topical JAK inhibitor now approved for children as young as two, backed by Phase III data showing 63% response rate at eight weeks
The analysis is based on diagnostic testing trends across its network and tracks changes in disease positivity and geographic patterns
The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy
The certification was issued following an audit by SGS, an independent testing, inspection and certification company, and covers the facility’s commercial-scale production of QS-21
The campaign combines Fortis Healthcare’s clinical expertise and hospital network with Takeda’s scientific expertise in dengue prevention and public health education
The discussions will examine how quality systems can move beyond compliance to become more predictive, risk-based and capable of learning from manufacturing experience
The collaboration is aimed at accelerating some of the most time-intensive regulatory work in drug development
The report examines how changing cultural attitudes toward beauty and aging are reshaping the aesthetic treatment landscap
SkinMedica says Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after two weeks
Nod as first new frontline regimen in more than a decade
iPHEX 2026 will focus on connecting Indian companies with buyers across markets
The deal gives AstraZeneca global control of a drug targeting a particularly aggressive form of lung cancer with significant unmet treatment needs
The agreement recognizes Sun Pharma’s investment in the US market by delaying Section 232 tariffs on innovative pharmaceutical products for more than two years
Appointment comes as Warburg Pincus-backed healthcare company looks to accelerate growth and expand beyond orthopaedics and women’s health
FDA classifies July inspection of InvaGen Pharmaceuticals’ Unit 3 facility as Voluntary Action Indicated following review of manufacturing operations
Roche unit plans end-to-end fill-finish site in Hillsboro to support portfolio and pipeline injectables
Lannett company commercialises first product from its inhalation pipeline in two strengths
Subscribe To Our Newsletter & Stay Updated
